Pacific Biosciences of California Inc. Stock
Pros and Cons of Pacific Biosciences of California Inc. in the next few years
Pros
Cons
Performance of Pacific Biosciences of California Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacific Biosciences of California Inc. | 8.870% | -15.273% | 8.591% | -80.049% | -83.426% | -92.896% | -66.723% |
| MicroVision Inc | 1.470% | 4.231% | 26.577% | -48.047% | -57.664% | -89.788% | 97.197% |
| Fonar Corp. New | 1.300% | 0.000% | 1.961% | 4.698% | -11.864% | 7.586% | -18.682% |
| Allscripts Healthcare | - | 0.000% | -3.614% | -31.034% | -13.514% | -31.034% | -17.797% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Evaluating the financial health of PacBio (US symbol PACB), a player in the Healthcare Equipment & Supplies sector, reveals a company currently grappling with numerous challenges, specifically in profitability and cash flow management. The financial statements indicate a significant struggle to turn revenue into profit, reflected in the negative net income over the past few years. Though there's potential in its technology and operations, the financial metrics point towards an urgent need for strategic improvements.
Market Potential and Innovation: PacBio operates in a rapidly evolving industry characterized by advancements in genomic technologies. With increasing demand for personalized medicine and genome sequencing, the company is positioned within a high-growth segment. This market potential supports the future revenue generation prospects.
Strong Asset Base: The total assets on the balance sheet amount to approximately $1.75 billion, reflecting a robust infrastructure for operations. The presence of intellectual property, shown through significant intangible assets ($456 million in 2023), can provide future value through product developments and licensing opportunities.
Comments